Claims
- 1. A compound of the invention having the formula: ##STR95## or a pharmaceutically acceptable salt thereof, wherein: Y is (CH.sub.2).sub.m O, ##STR96## wherein m is an integer chosen from 0, 1, 2, 3, 4, 5 and 6; E is CH or N;
- D is O, S or NH;
- A is ##STR97## wherein n is an integer chosen from 0, 1, 2, 3, 4, 5 and 6; B is ##STR98## wherein R.sup.7 is hydrogen, C.sub.1-8 alkyl, or aryl;
- R.sup.10 is carboxyC.sub.0-6 alkyl, benzyloxycarbonylamino, C.sub.1-8 alkylsulfonylamino, phenyl C.sub.0-8 alkylaminocarbonylamino C.sub.0-6 alkyl, hydrogen, arylsulfonylamino, wherein aryl is unsubstituted or substituted with halogen, or alkylarylsulfonylamino; and
- R.sup.11 is OH or C.sub.1-8 alkyloxy.
- 2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is (CH.sub.2).sub.n or ##STR99##
- 3. A compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein
- Y is --CH.sub.2 O-- or --CH.sub.2 CH.sub.2 O--; and
- B is ##STR100##
- 4. A compound of claim 3, or the pharmaceutically acceptable salt thereof, which is 5-�2-(4-Piperidinylethyl)oxy!-2-indolecarbonyl-2(S)-phenylsulfonylamino-.beta.-alainine.
- 5. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
Parent Case Info
This is a division of application Ser. No. 08/416,770 filed May 31, 1995 now U.S. Pat. No. 5,559,127, which is the national phase of PCT/US93/09730, filed on Oct. 12, 1993, which is Continuation In Part of Ser. No. 07/960668, filed on Oct. 14, 1992, abandoned.
Non-Patent Literature Citations (2)
Entry |
Hartman GD et al. J. Med. Chem. 35, 4640-4642, 1992. |
Ford-Hutchinson AW. et al. Can. J. Physiol. Pharmacol. 67, 989-993, 1989. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
416770 |
May 1995 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
960668 |
Oct 1992 |
|